Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

NSS Labs Initiates Group Test Analysis Coverage of SD-WAN Market and Call for Industry Input


Posted on: 21 Sep 17

AUSTIN, Sept. 21, 2017 (GLOBE NEWSWIRE) -- NSS Labs, Inc., the global leader in operationalizing cybersecurity, today announced that it is expanding on its strong core foundation of point-in-time test validation and continuous security validation with the introduction of the Software-Defined Wide Area Network (SD-WAN) Group Test. This forthcoming public group test of market-leading SD-WAN solutions will include emphasis on the WAN edge, traffic optimization, and security components of SD-WAN, which are driving accelerated adoption of SD-WAN among enterprise customers. As part of today’s announcement, the company is also issuing a call for input from both enterprises and SD-WAN vendors to help shape and evolve its forthcoming SD-WAN Group Test and accompanying methodology. 

Adoption of SD-WAN is expected to accelerate over the next five years. The market is estimated to grow at a staggering 69% compound annual growth rate, reaching $8 billion by 2021, according to IDC. 

The combination of WAN optimization, routing capabilities, and security capabilities are fundamental to enterprises as they rationalize the migration from an existing Multiprotocol Label Switching (MPLS) private network to a pure or hybrid SD-WAN deployment strategy. While SD-WAN offers compelling value and cost benefits, SD-WAN architectures leverage the Internet and rely on WAN optimization and key encryption capabilities such as SSL/TLS and IPSec to deliver end-to-end value to customers. SD-WAN implementation options in the market vary and can include overlays to existing security solutions, or Customer Premise Equipment (CPE) with embedded security elements such as next generation firewall (NGFW) and next generation intrusion prevention system (NGIPS) functionality. As enterprises investigate SD-WAN options to support their individual use case requirements, they are seeking ways to narrow their proof-of-concept (PoC) candidates. NSS Labs’ SD-WAN Group Test v1.0 will provide empirical, fact-based data to empower enterprises with relevant information around SD-WAN architectures and their key capabilities to help drive informed purchasing decisions.   

“The SD-WAN market is quickly emerging as enterprises migrate to the SD-WAN architecture, keeping WAN edge, traffic optimization, and security in mind to support their use case requirements,” said Jason Brvenik, Chief Technology Officer at NSS Labs. “We believe that our SD-WAN Group Test will provide valuable insights regarding the current state of WAN edge, performance, and overall security effectiveness and capabilities that SD-WAN products in the market offer today. We encourage and invite enterprises and vendors to collaborate with us regarding use cases and the test methodology to help highlight the strengths and differentiation available in the SD-WAN market.”

NSS Labs has a longstanding history in testing enterprise-class security products. Its rigorous, independent Group Tests of the top security technologies used today by Global 2000 companies offer vendor-neutral analysis and provide the industry’s most comprehensive review of security effectiveness, performance, and total cost of ownership to inform decision-making. These Group Tests are based on real-world use cases and are a resource enterprises have come to rely on for fact-based, empirical data to evolve their security architectures. Throughout 2017, NSS Labs has released Group Test results for several categories of mature and evolving cybersecurity products including Advanced Endpoint Protection, Next-Generation FirewallsData Center Firewalls, and Web Application Firewalls

NSS Labs conducts both public tests, which are published in NSS Labs’ research library, and private engineering engagements (under NDA) for enterprises, government organizations, and vendors. All test engagements leverage the combined strengths of NSS Labs’ unmatched testing expertise, CAWS continuous security validation platform, and unique threat capture capabilities to independently verify the security effectiveness of products. 

Enterprises that wish to provide feedback regarding the forthcoming SD-WAN Group Test and the associated test methodology can send their feedback to SD-WANenterprise@nsslabs.com. Vendors should send their feedback to SD-WANvendor@nsslabs.com.

Additional Resources: 

About NSS Labs, Inc.
NSS Labs, Inc. is the global leader in operationalizing cybersecurity, empowering enterprises by providing relevant information to reduce the operational burden of cybersecurity and address crucial gaps in their cybersecurity efforts. Our unmatched and well-respected foundation in security testing, along with our enterprise research and global threat analysis capabilities, provide the basis for our CAWS Continuous Security Validation Platform, an advanced platform that substantiates the effectiveness of enterprise security controls and uncovers unmitigated risks to enterprise systems. Using fact-based threat data and objective risk information, CAWS enables businesses to strengthen their cyber risk posture, continuously validate their security controls and take timely action to mitigate threats to their Operating Systems and applications. CISOs, Chief Security Architects, SOC and Threat Analysts, and SOC and information security professionals from many of the world's largest and most demanding enterprises rely on trusted insights from NSS Labs. For more information, visit www.nsslabs.com.

Contact:
Tom Resau
W2 Communications
Phone: +1 703-877-8103
tom@w2comm.com

GlobeNewswire
globenewswire.com

Last updated on: 22/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.